CARB-X announced two new investments on Tuesday. The first, worth up to $8.77 million, will go to Germany’s Helmholtz Centre for Infection Research (HZI) and the Dortmund-based Lead Discovery Center to develop a drug to prevent S. aureus-induced lung tissue damage in pneumonia patients. The second award—up to $6.31 million to a team of HZI-affiliated researchers—will fund the development of a new treatment for P. aeruginosa infections in cystic fibrosis patients.

In other news, the…


German biotech Evotec announced this week that it will work with the Helmholtz Centre for Infection Research to discover new drugs for tuberculosis and malaria. The Gates Foundation is providing $2.6 million to fund the three-year project. The press release did not disclose further timelines or details.


Ascenion GmbH, the technology transfer partner of Germany’s Helmholtz Center for Infection Research (HZI), announced last week that it has sold to Serum Institute of India (SII) its majority stake in HZI spin-off biotech Vakzine Projekt Management (VPM).

SII has been working with VPM since 2012 to develop VPM’s Phase 3 recombinant BCG tuberculosis vaccine under license.

In the undisclosed cash deal, SII gains ninety percent of the company and a 10-person team based in Hanover.